About this trial

The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone, in adults following thoracic surgery. Major inpatient thoracic surgeries (TS) for lung disease are common and extremely painful surgeries and are associated with sever post-surgical pain, high incidence of chronic post-surgical pain (CPSP), excess opioid use, costly immediate postoperative opioid adverse events (AEs), and long hospital stays. This study is aiming to develop proactive risk prediction algorithms for precision surgical pain relief in adult TS patients through comparison of actual clinical outcomes with standard of care to predicted outcomes based on personalized risk assessments.

Eligibility criteria

Qualifiers

>18 years

American Society of Anesthesiologists (ASA) Physical Status 1, 2, 3

Undergoing thoracic surgery (TS; pneumonectomy, lobectomy and segmentectomy)

Disqualifiers

Children (<18 years)

Pregnant women

American Society of Anesthesiologists (ASA) Physical Status 4 or above

Non-English speaking

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

4
UPMC Mercy Hospital15219, PittsburghPennsylvania, United States
UPMC Passavant Hospital15237, PittsburghPennsylvania, United States
UPMC Presbyterian Hospital15213, PittsburghPennsylvania, United States
UPMC Shadyside Hospital15232, PittsburghPennsylvania, United States

Sponsors and collaborators

OpalGenix, Inc

Lead sponsor